Study details
Enrolling now
Denosumab for Type 1 Diabetes
City of Hope Medical Center
NCT IDNCT06524960ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
45
Study length
about 3.1 years
Ages
18–50
Locations
3 sites in AL, CA, IN
About this study
This trial is testing whether denosumab, a medication approved to treat osteoporosis and bone cancer, can protect beta cells in people with early type 1 diabetes. The goal is to determine if denosumab improves beta cell function and blood sugar control.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Denosumab
PhasePhase 1/Phase 2
DrugDenosumab
Routeinjection
Primary goalPrimary efficacy endpoint
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
denosumab
Drug routes
injection, subcutaneous
Endpoints
Primary: Primary efficacy endpoint, Primary safety endpoint
Secondary: HbA1c improvement
Body systems
Endocrinology